(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Share This 
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This 
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Share This 
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Share This 
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Share This 
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This 
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Share This 
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Share This Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Share This Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Share This Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Share This Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
Share This
Addressing Endocrine Disorders and Metabolic Diseases with Expert Bioanalysis
From discovery through every phase of biologic development, BioAgilytix offers comprehensive bioanalytical support for every stage of your metabolic, diabetes, and obesity therapeutics development. Our services are supported by decades of scientific expertise in even the most complex challenges related to bioanalysis of drugs addressing endocrine disorders and metabolic diseases.
The global metabolic disease therapeutics market is set to grow at a steady pace in coming years, as metabolic diseases have become more common, especially is North America. The benefit of increased focus on these conditions is that today, treatment of metabolic diseases can truly begin at the source. Using information about the patient’s genetics, scientists and physicians can more accurately target the exact enzyme deficiency, and gene therapy has shown potential as an effective treatment for a number of inherited metabolic diseases in recent years.
In order to carry out these new and complex large molecule studies effectively, pharmaceutical and biotechnology companies need a trusted CRO partner that is well-versed in the complexities of endocrine disorders and metabolic diseases, and how to accurately assess the impact that large molecule drug candidates have on the regulation of various body functions.
Today’s pharmaceutical and biotechnology organizations need a scientific partner that can help them constantly innovate and evolve to meet novel requirements of developing increasingly effective (but increasingly complex) biotherapeutic innovations.
BioAgilytix has a deep understanding of metabolic and endocrine diseases and the large molecule drugs used to treat them. Our services span from the discovery phase through Phase I, II, III, and IV, and our GLP/GMP lab ensures that assay data upholds the requirements of regulated bioanalysis.
While our scientists have diverse experience within the realm of metabolic diseases, we have particular expertise analyzing compounds and biotherapeutics that target conditions including diabetes mellitus, glucose tolerance hypertension, insulin resistance, hormone replacement, and obesity.
The following services are regularly used in metabolic-related studies at BioAgilytix:
Explore our array of white papers, articles, and videos to gain deeper insight into our small and large molecule expertise, and to stay updated with the latest news and research coming from the field of bioanalysis.
We understand that with a growing need for innovative treatments for inherently complex metabolic and endocrine diseases, pharmaceutical and biotechnology companies are in need of an outsourcing partner that can help efficiently develop safer, more effective biotherapeutic solutions.
BioAgilytix is an experienced provider of metabolic disease-related bioanalytical services, with over 30 validated biomarker assays for diabetes and obesity available for sample analysis both in single and multiplex formats. In fact, our scientists have contributed to several diabetes drugs in late clinical trials and have performed over 200,000 determinations. We leverage our veteran insights, gained from decades of real-world experience, to help you masterfully navigate scientific and regulatory complexities at every step of development.
If you are looking for an expert partner to help efficiently and effectively support the entirety of the metabolic disease research process, look no further than BioAgilytix.
